|
ATE180280T1
(de)
|
1991-03-05 |
1999-06-15 |
Wellcome Found |
Expression rekombinanter proteine in attenuierten bakterien
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
KR100283541B1
(ko)
|
1991-10-25 |
2001-03-02 |
크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 |
신규 사이토킨
|
|
CA2143299A1
(en)
|
1992-09-04 |
1994-03-17 |
University Of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
WO1995014487A1
(en)
|
1993-11-24 |
1995-06-01 |
The Australian National University |
Treatment of viral disease with cd40l peptide
|
|
AU699291B2
(en)
|
1995-03-01 |
1998-11-26 |
Immunex Corporation |
Method for stimulating an immune response
|
|
MX9709447A
(es)
|
1995-06-07 |
1998-02-28 |
Immunex Corp |
Nueva muteina cd4ol.
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
JP2001526241A
(ja)
|
1997-12-19 |
2001-12-18 |
イミュネックス・コーポレーション |
Ｈｉｖ感染に対する感受性を低下させるための方法
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
WO2000014240A2
(en)
|
1998-09-04 |
2000-03-16 |
Creatogen Aktiengesellschaft |
Attenuated salmonella sp12 mutants as antigen carriers
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
JP2003508016A
(ja)
|
1999-04-16 |
2003-03-04 |
エフ．ホフマン−ラ ロシュ アーゲー |
Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
EP1246643A4
(en)
|
1999-10-14 |
2005-05-11 |
Jeffery A Ledbetter |
DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
|
|
MXPA00012796A
(es)
|
1999-12-28 |
2002-05-23 |
Akzo Nobel Nv |
Vacuna de salmonella.
|
|
DE60136334D1
(en)
|
2000-02-02 |
2008-12-11 |
Us Health |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
|
AU5695701A
(en)
|
2000-03-17 |
2001-10-03 |
Upjohn Co |
Salmonella vaccine materials and methods
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
AU2001273009A1
(en)
|
2000-06-26 |
2002-01-08 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
AU2002221780A1
(en)
|
2000-10-31 |
2002-05-15 |
F.Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
BR0209689A
(pt)
|
2001-05-15 |
2006-02-07 |
Long Island Jewish Res Inst |
Uso de fragmento de hmg como agente anti-inflamatório
|
|
EP1407004B1
(en)
|
2001-05-15 |
2009-08-05 |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
Ex-vivo priming for generating cd40-ligand specific cytotoxic t lymphocytes to treat autoimmune and allergic disease
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
CA2470640A1
(en)
|
2001-12-19 |
2003-06-26 |
Alcedo Biotech Gmbh |
Use of hmgb proteins and nucleic acids that code therefor
|
|
PL208287B1
(pl)
|
2001-12-21 |
2011-04-29 |
Immunex Corp |
Polipeptyd fuzyjny, sposób jego wytwarzania oraz kodujący go kwas nukleinowy, komórka gospodarza, rekombinowany wektor oraz sposób jego konstruowania
|
|
KR100965026B1
(ko)
|
2002-02-13 |
2010-06-21 |
이뮤놀로지 래보러토리스 인코포레이티드 |
미생물 감염증을 치료하기 위한 조성물 및 방법
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
WO2003096812A1
(en)
|
2002-04-15 |
2003-11-27 |
Washington University |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
WO2004046345A2
(en)
|
2002-11-20 |
2004-06-03 |
Critical Therapeutics, Inc. |
Use of hmgb fragments as anti-inflammatory agents
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
AU2003295653B2
(en)
|
2002-11-20 |
2007-08-16 |
The Feinstein Institute Of Medical Research |
Use of HMGB polypeptides for increasing immune responses
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
EP1668035A2
(en)
|
2003-09-11 |
2006-06-14 |
Critical Therapeutics, Inc. |
Monoclonal antibodies against hmgb1
|
|
WO2005035570A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Variants of cd40l protein
|
|
CA2546873A1
(en)
|
2003-11-21 |
2005-06-02 |
Ace Biosciences A/S |
Surface-located campylobacter jejuni polypeptides
|
|
WO2005058950A2
(en)
|
2003-12-11 |
2005-06-30 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
WO2005103073A2
(en)
|
2004-04-27 |
2005-11-03 |
Intercell Ag |
Td antigens
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
WO2006083301A2
(en)
|
2004-06-17 |
2006-08-10 |
Medimmune, Inc. |
Immunogenic compositions comprising hmgb1 polypeptides
|
|
EP1765857A2
(en)
*
|
2004-07-02 |
2007-03-28 |
Metanomics GmbH |
Process for the production of fine chemicals
|
|
EP1814576A2
(en)
|
2004-07-20 |
2007-08-08 |
Critical Therapeutics, Inc. |
Combination therapies of hmgb and complement inhibitors against inflammation
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
US20080145931A1
(en)
|
2004-10-07 |
2008-06-19 |
Argos Therapeutics, Inc. |
Mature Dendritic Cell Compositions and Methods of Culturing Same
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
WO2006130525A2
(en)
|
2005-05-31 |
2006-12-07 |
Sidney Kimmel Cancer Center |
Methods for immunotherapy of cancer
|
|
EP1909834A2
(en)
|
2005-07-18 |
2008-04-16 |
Critical Therapeutics, Inc. |
Use of hmgb1 antagonists for the treatment of inflammatory skin conditions
|
|
JP2009511452A
(ja)
|
2005-10-07 |
2009-03-19 |
プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ |
Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ
|
|
AU2006311752A1
(en)
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
WO2007130725A2
(en)
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
|
CU23576A1
(es)
|
2006-02-28 |
2010-09-30 |
Ct Ingenieria Genetica Biotech |
Antígenos vacunales quiméricos contra el virus de la influenza aviar
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
US8802419B2
(en)
|
2006-03-02 |
2014-08-12 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
JP2009535063A
(ja)
*
|
2006-05-04 |
2009-10-01 |
アブマクシス・インコーポレイテツド |
異種間及び複数種提示系
|
|
JP5683811B2
(ja)
|
2006-07-27 |
2015-03-11 |
タケダ ヴァクシーンズ， インコーポレイテッド |
キメラインフルエンザウイルス様粒子
|
|
JP2010500034A
(ja)
|
2006-08-09 |
2010-01-07 |
メッドイミューン バクシーンズ，インコーポレイティド |
インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
|
|
EP2857038B1
(en)
|
2006-09-18 |
2019-04-10 |
The Board of Trustees of the University of Arkansas |
Compositions and methods of enhancing immune responses
|
|
EP2086579A2
(en)
|
2006-10-27 |
2009-08-12 |
Dow AgroSciences LLC |
Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine
|
|
WO2008109825A2
(en)
|
2007-03-08 |
2008-09-12 |
Mayo Foundation For Medical Education And Research |
Inducing immune-mediated tumor cell death
|
|
CA2688548A1
(en)
|
2007-05-02 |
2009-01-15 |
Emory University |
Enhancement of glycoprotein incorporation into virus-like particles
|
|
US9125854B2
(en)
|
2007-10-30 |
2015-09-08 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
PT2214701T
(pt)
|
2007-11-01 |
2016-11-02 |
Univ Guelph |
Composições e métodos de potenciar respostas imunes a eimeria
|
|
US8669113B2
(en)
|
2008-04-03 |
2014-03-11 |
Becton, Dickinson And Company |
Advanced detection of sepsis
|
|
JP5660889B2
(ja)
|
2008-04-30 |
2015-01-28 |
株式会社ジェノミックス |
末梢循環への骨髄由来多能性幹細胞動員薬
|
|
JP5710482B2
(ja)
|
2008-09-11 |
2015-04-30 |
アンスティテュ・パストゥール |
Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
|
|
US8163281B2
(en)
|
2009-03-04 |
2012-04-24 |
The Regents Of The University Of Michigan |
Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
|
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
|
NO2525817T3
(enExample)
|
2010-01-21 |
2018-01-06 |
|
|
|
PL2365332T3
(pl)
|
2010-03-10 |
2013-10-31 |
Pasteur Institut |
HMGB1 i przeciwciała anty-HMGB1 u pacjentów zakażonych HIV, zwłaszcza z zaburzeniami neurologicznymi
|
|
US8865653B2
(en)
|
2010-04-22 |
2014-10-21 |
Institut Gustave Roussy |
Method of treatment for immunogenic treatment resistant cancer
|
|
BR112012031211A2
(pt)
*
|
2010-06-09 |
2018-01-30 |
Univ Arkansas |
métodos e vacina para reduzir a infecção causada pelo campylobacter
|
|
WO2014028776A1
(en)
|
2012-08-15 |
2014-02-20 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
AU2013338153B2
(en)
|
2012-10-29 |
2018-06-21 |
The Board Of Trustees Of The University Of Arkansas |
Novel mucosal adjuvants and delivery systems
|
|
EP2956165B1
(en)
|
2013-02-14 |
2019-09-11 |
The Board of Trustees of the University of Arkansas |
Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
|
|
CN105142653B
(zh)
*
|
2013-03-15 |
2019-11-15 |
阿肯色大学评议会 |
增强对肠病原体免疫应答的组合物和方法
|
|
CN106535932A
(zh)
|
2014-06-05 |
2017-03-22 |
阿肯色大学评议会 |
抗体引导的疫苗和用于产生快速成熟的免疫应答的方法
|